The Predictive Potential of Genomics in Multiple Myeloma
Release Date: March 22, 2017
Expiration Date: March 22, 2018
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Predictive markers have the potential to guide treatment selection and personalize therapeutic strategies for patients with multiple myeloma. Cytogenetic abnormalities, including del(17p), t(4;14) and t(14;16), are hallmarks of high-risk disease, but these genomic aberrations have also been implicated as potential predictive markers. Other genomic predictive markers are under investigation, such as t(14;20) and the SKY92 signature identified through gene expression profiling. In this activity, participants will learn about various genomic predictive markers under investigation and their potential to guide treatment decisions for patients with multiple myeloma.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in treating patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Describe testing strategies to obtain genomic information of predictive value in patients with multiple myeloma
- Outline drug selection strategies based on high-risk cytogenetics in patients with multiple myeloma
- Recognize investigational predictive markers in multiple myeloma, including genetic signatures identified through gene expression profiling
The Predictive Potential of Genomics in Multiple Myeloma – Saad Z. Usmani, MD, FACP
Instructions for Participation and Credit
This activity is eligible for credit through March 22, 2018. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders Program
Director, Clinical Research in Hematologic Malignancies
Levine Cancer Institute/Carolinas HealthCare System
Charlotte, North Carolina
Clinical Professor of Medicine, UNC-Chapel Hill School of Medicine
Chapel Hill, North Carolina
Dr. Saad Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr. Usmani is a Clinical Professor of Medicine at the UNC School of Medicine, Chief of the Plasma Cell Disorder Program, and Director of Clinical Research in Hematologic Malignancies at the Levine Cancer Institute/Carolinas HealthCare System.
Dr. Usmani is a member of the International Myeloma Working Group, SWOG Myeloma Committee, American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), and the American Society of Bone Marrow Transplantation. He has served on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, the ASH Committee on Plasma Cell Neoplasia, and the NCI Myeloma Steering Committee. Dr. Usmani is on the editorial review board of numerous medical journals, has authored/co-authored more than 80 peer-reviewed research manuscripts and 100 abstracts at national and international meetings. A specialist in hematology, medical oncology and bone marrow transplantation, Dr. Usmani’s clinical and translational research has been focused on plasma cell disorders, specifically high-risk multiple myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-137-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Saad Usmani has received honoraria related to formal advisory activities from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Sanofi, Seattle Genetics, Inc., and Skyline Diagnostics B.V., as well as speakers’ bureau activities from Amgen, Celgene, Sanofi, and Takeda Oncology. He has received grant support related to research activities from Amgen, Array BioPharma, Bristol-Myers Squibb Company, Celgene, Janssen, Pharmacyclics, Inc., and Sanofi.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.